Comment on "A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder"'
CNS Drugs. 2025 Jan 2.
doi: 10.1007/s40263-024-01152-6.
Online ahead of print.